Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma.
(2022) HemaSphere — Vol. 6, n° 2, p. e672 [1-4] (2022)
Files
HouotRHemasphere2022.pdf
Open Access - Adobe PDF
- 495.9 KB
Details
- Authors
- Abstract
- (en) Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of aggressive lymphomas, which usually carry a poor prognosis. Malignant T cells may overexpress programmed death ligand 1 (PD-L1), which signals via programmed death-1 (PD-1) receptor, and provides an inhibitory signal on normal T-cells further suppressing antitumor immunity. They can also express PD1, which may act as a tumor suppressor on malignant T cells. Thus, in principle, blocking the PD1/PDL1 synapse in PTCL may lead to either tumor regression or progression. Nevertheless, PD1-blockade demonstrated antitumor activity in monotherapy in patients with relapsed/refractory (R/R) PTCL with an ORR around 33%. [...]
- Affiliations
Citations
Houot, R., Poeschel, V., Altmann, B., Angel, S., Thurner, L., Illmer, T., André, M., Dreyling, M., Maisonneuve, H., Tilly, H., Mayer, S., Casasnovas, O., Le Gouill, S., Offner, F., Cartron, G., Kerkhoff, A., Weber, T., Hoffmann, J., Ziepert, M., et al. (2022). Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. HemaSphere, 6(2), e672 [1-4]. https://doi.org/10.1097/HS9.0000000000000672 (Original work published 2022)